876 related articles for article (PubMed ID: 20015974)
1. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
2. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
3. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
4. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
6. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
[TBL] [Abstract][Full Text] [Related]
10. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
12. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
14. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
[TBL] [Abstract][Full Text] [Related]
15. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
16. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
17. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
18. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
19. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A
J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
